CRL three-lens brief
Evidence-based stock research on CRL. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $199.33 — 17% above current (15 analysts). · Currently unprofitable on a trailing basis — no P/E multiple available.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $199.33 — 17% above current (15 analysts).
- Debt-to-equity of 81.9 — balance-sheet-heavy.
CRL closed at $169.80 (+1.23%) as of 2026-04-25. Market cap: $8.38B. Positives: analyst mean target $199.33 — 17% above current (15 analysts).. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; debt-to-equity of 81.9 — balance-sheet-heavy.. Last quarter: Revenue $994.23M, net income -$276.56M, free cash flow $572.38M.
Why three lenses on CRL, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CRLacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CRL" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CRL brief"></iframe>